Latest & greatest articles for sepsis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sepsis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on sepsis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for sepsis

381. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial.

Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2000

382. Hypoproteinemia predicts acute respiratory distress syndrome development, weight gain, and death in patients with sepsis

Hypoproteinemia predicts acute respiratory distress syndrome development, weight gain, and death in patients with sepsis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2000

383. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group.

Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. 11041396 2000 11 07 2000 11 07 2016 11 24 0140-6736 356 9234 2000 Sep 16 Lancet (London, England) Lancet Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group (...) . 961-7 Endotoxin is a primary trigger of the inflammatory processes that lead to shock, multiorgan failure, and purpura fulminans in meningococcal sepsis. Bactericidal/permeability-increasing protein (BPI) is a natural protein, stored within the neutrophil granules, that binds to and neutralises the effects of endotoxin in vitro, in laboratory animals, and in humans. To establish whether a recombinant 21-kDa modified fragment of human BPI (rBPI21), containing the active antimicrobial and endotoxin

Lancet2000

384. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators.

E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. 10755499 2000 04 13 2000 04 13 2016 10 17 0098-7484 283 13 2000 Apr 05 JAMA JAMA E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. 1723-30 Knowledge and understanding of gram-negative sepsis have grown over the past 20 years, but the ability to treat severe sepsis successfully has not. To assess (...) the efficacy and safety of E5 in the treatment of patients with severe gram-negative sepsis. A multicenter, double-blind, randomized, placebo-controlled trial conducted at 136 US medical centers from April 1993 to April 1997, designed with 90% power to detect a 25% relative risk reduction, incorporating 2 planned interim analyses. Intensive care units at university medical centers, Veterans Affairs medical centers, and community hospitals. Adults aged 18 years or older, with signs and symptoms consistent

JAMA2000

385. Vancomycin for prophylaxis against sepsis in preterm neonates.

Vancomycin for prophylaxis against sepsis in preterm neonates. BACKGROUND: Nosocomial, late onset sepsis occurs in up to 50% of infants of less than 1000gm at birth. The commonest organism isolated is coagulase negative staphylococcus (CoNS). A number of studies have evaluated the efficacy or prophylactic low dose vancomycin given either as a continuous infusion added to the infant's hyperalimentation fluid or by intermittent intravenous administration and these studies in very low birth weight (...) infants are the subject of this review. OBJECTIVES: To evaluate the safety and efficacy of vancomycin prophylaxis for the prevention of late-onset sepsis, coagulase negative staphylococcal sepsis, mortality, and effects on length of stay, total vancomycin exposure, evidence of vancomycin toxicity, and the development of vancomycin resistant organisms in the preterm neonate. SEARCH STRATEGY: Searches were made of Medline, (MeSH terms: Vancomycin and Sepsis; limits: age groups, newborn infants

Cochrane2000

386. Intravenous immunoglobulin for treating sepsis and septic shock.

Intravenous immunoglobulin for treating sepsis and septic shock. OBJECTIVES: Death from severe sepsis and septic shock is common, and researchers have explored whether antibodies to the endotoxins in some bacteria reduces mortality. This review summarises the effects of intravenous immunoglobulin (IVIG) in patients with bacterial sepsis or septic shock on mortality, bacteriological failure rates, and duration of stay in hospital. SEARCH STRATEGY: We searched the Cochrane Controlled Trials (...) Register, Medline 1966 to April 1999, EMBASE 1988 to February 1999; we contacted investigators active in the field for unpublished data. SELECTION CRITERIA: Randomised trials comparing intravenous immunoglobulin (monoclonal or polyclonal) with placebo or no intervention, in patients with bacterial sepsis or septic shock. DATA COLLECTION AND ANALYSIS: Inclusion criteria, trial quality assessment, and data abstraction were done in duplicate. We conducted pre-specified subgroup analyses by type

Cochrane2000

387. Preventing early-onset group B streptococcal sepsis: strategy development using decision analysis

Preventing early-onset group B streptococcal sepsis: strategy development using decision analysis Preventing early-onset group B streptococcal sepsis: strategy development using decision analysis Preventing early-onset group B streptococcal sepsis: strategy development using decision analysis Benitz W E, Gould J B, Druzin M L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) of the study Integrated obstetrical and neonatal regimens appropriate to the population served should be adopted by each obstetrical service. Surveillance of costs, complications, and benefits will be essential to guide continued iterative improvement of these strategies. Source of funding Sources of funding were not stated. Bibliographic details Benitz W E, Gould J B, Druzin M L. Preventing early-onset group B streptococcal sepsis: strategy development using decision analysis. Pediatrics 1999; 103(6

NHS Economic Evaluation Database.1999

388. Applying epidemiology-based outcomes research to clinical decision-making: a hypothetical model of biotechnology therapy in gram-negative sepsis

Applying epidemiology-based outcomes research to clinical decision-making: a hypothetical model of biotechnology therapy in gram-negative sepsis Applying epidemiology-based outcomes research to clinical decision-making: a hypothetical model of biotechnology therapy in gram-negative sepsis Applying epidemiology-based outcomes research to clinical decision-making: a hypothetical model of biotechnology therapy in gram-negative sepsis Wang E C, Grasela T H, Walawander C A Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Biotechnology therapy in gram-negative sepsis. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The 2 populations studied were patients with nosocomial

NHS Economic Evaluation Database.1999

389. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial

Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club1999

390. Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group.

Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group. PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club1999

391. A randomized and controlled trial of the effect of treatment aimed at maximizing oxygen delivery in patients with severe sepsis or septic shock

A randomized and controlled trial of the effect of treatment aimed at maximizing oxygen delivery in patients with severe sepsis or septic shock PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club1999

392. Impact of immunomodulating therapy on morbidity in patients with severe sepsis.

Impact of immunomodulating therapy on morbidity in patients with severe sepsis. PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club1999

393. Effects of ibuprofen on the physiology and survival of hypothermic sepsis

Effects of ibuprofen on the physiology and survival of hypothermic sepsis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club1999

394. Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis

Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis Jenson H B, Pollock B H Authors' objectives To determine the effectiveness of intravenous immune globulin (IVIG) in the prevention and treatment of neonatal (...) sepsis. Searching MEDLINE (no dates given) was searched for English language papers plus identification of studies by "personal knowledge". Study selection Study designs of evaluations included in the review Peer-reviewed, prospective randomised trials including a concurrent control group receiving either placebo or no IVIG treatment were eligible for inclusion. IVIG administration had to be given shortly after birth for prophylaxis, or on clinical diagnosis of sepsis for treatment. Specific

DARE.1997

395. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group.

Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. 9020273 1997 02 20 1997 02 20 2016 10 17 0098-7484 277 6 1997 Feb 12 JAMA JAMA Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled (...) trial. CP-0127 SIRS and Sepsis Study Group. 482-7 To test the effect of a novel bradykinin antagonist, deltibant (CP-0127), on survival, organ dysfunction, and other outcomes in patients with the systemic inflammatory response syndrome (SIRS) and presumed sepsis. Multicenter, randomized, placebo-controlled, double-blind, parallel, dose-ranging trial. Follow-up for 28 days or until death. A total of 47 US referral hospitals. A total of 504 patients with SIRS and documented evidence of infection plus

JAMA1997

396. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.

The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. 9070471 1997 03 27 1997 03 27 2013 11 21 0028-4793 336 13 1997 Mar 27 The New England journal of medicine N. Engl. J. Med. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. 912-8 In patients with sepsis the production of arachidonic acid metabolites by cyclooxygenase increases, but the pathophysiologic role (...) of these prostaglandins is unclear. In animal models, inhibition of cyclooxygenase by treatment with ibuprofen before the onset of sepsis reduces physiologic abnormalities and improves survival. In pilot studies of patients with sepsis, treatment with ibuprofen led to improvements in gas exchange and airway mechanics. From October 1989 to March 1995, we conducted a randomized, double-blind, placebo-controlled trial of intravenous ibuprofen (10 mg per kilogram of body weight [maximal dose, 800 mg], given every six

NEJM1997

397. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.

p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. 9153367 1997 05 29 1997 05 29 2016 10 17 0098-7484 277 19 1997 May 21 JAMA JAMA p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. 1531-8 To evaluate the safety and efficacy of p55 (...) tumor necrosis factor receptor fusion protein, a recombinant chimeric protein of human p55 (type I) tumor necrosis factor receptor (CD120a) extracellular domain and IgG1 sequences (referred to as p55-IgG), in the treatment of patients with severe sepsis or septic shock. Randomized, prospective, multicenter, double-blind, placebo-controlled clinical trial. Forty-four community and university-affiliated hospitals in the United States and Europe. There were 498 patients enrolled in this clinical trial

JAMA1997

398. Percutaneous central venous catheter-related sepsis in the neonate: an analysis of the literature from 1990 to 1994

Percutaneous central venous catheter-related sepsis in the neonate: an analysis of the literature from 1990 to 1994 Percutaneous central venous catheter-related sepsis in the neonate: an analysis of the literature from 1990 to 1994 Percutaneous central venous catheter-related sepsis in the neonate: an analysis of the literature from 1990 to 1994 Trotter C W Authors' objectives To evaluate methods of reducing catheter-related sepsis (CRS) in high-risk neonates. Searching MEDLINE, CINAHL (...) on the methods of this review. Literature searches were performed from 1990 onwards as the author states that she had previously reviewed literature published prior to 1990; however, no reference for this is provided. Implications of the review for practice and research There is a need for randomised controlled trials of methods to reduce CRS. Bibliographic details Trotter C W. Percutaneous central venous catheter-related sepsis in the neonate: an analysis of the literature from 1990 to 1994. Neonatal

DARE.1996

399. Randomized, placebo-controlled, double blinded trial of dexamethasone in African children with sepsis

Randomized, placebo-controlled, double blinded trial of dexamethasone in African children with sepsis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club1996

400. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. 8637514 1996 07 05 1996 07 05 2006 11 15 0028-4793 334 26 1996 Jun 27 The New England journal of medicine N. Engl. J. Med. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. 1697-702 A recombinant, soluble fusion protein that is a dimer of an extracellular portion of the human tumor

NEJM1996